Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …

The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell
killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell …

Glioblastoma (GBM) is the most aggressive primary malignant brain cancer and urgently
requires effective treatments. Chimeric antigen receptor T (CAR-T) cell therapy offers a …

Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous
system in adults. Ever more recent papers are focusing on understanding the role of the …

Hypoxia‐induced M2 phenotypes of tumor associated macrophages (TAMs) promote the
development and chemoresistance of multiple types of cancers, including glioblastoma …

Simple Summary This paper summarizes the crosstalk between tumor/non-tumor cells and
other elements of the glioblastoma (GB) microenvironment. In tumor pathology, glial cells …

Methods RNA-seq, RT-qPCR, and flow cytometry were used to determine IL15Rα
expression in paired peripheral and tumor-infiltrating immune cells of GBM patients and two …

Glioma is the most common primary intracranial tumor and has the greatest prevalence of all
brain tumors. Treatment resistance and tumor recurrence in GBM are mostly explained by …

GBM is the most common primary brain tumor in adults, and the aggressive nature of this
tumor contributes to its extremely poor prognosis. Over the years, the heterogeneous and …